Cargando…
International consensus on the use of tau PET imaging agent (18)F-flortaucipir in Alzheimer’s disease
PURPOSE: Positron emission tomography (PET) with the first and only tau targeting radiotracer of (18)F-flortaucipir approved by FDA has been increasingly used in depicting tau pathology deposition and distribution in patients with cognitive impairment. The goal of this international consensus is to...
Autores principales: | Tian, Mei, Civelek, A. Cahid, Carrio, Ignasi, Watanabe, Yasuyoshi, Kang, Keon Wook, Murakami, Koji, Garibotto, Valentina, Prior, John O., Barthel, Henryk, Zhou, Rui, Hou, Haifeng, Dou, Xiaofeng, Jin, Chentao, Zuo, Chuantao, Zhang, Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803772/ https://www.ncbi.nlm.nih.gov/pubmed/34978595 http://dx.doi.org/10.1007/s00259-021-05673-w |
Ejemplares similares
-
International Nuclear Medicine Consensus on the Clinical Use of Amyloid Positron Emission Tomography in Alzheimer’s Disease
por: Tian, Mei, et al.
Publicado: (2022) -
Unsupervised [(18)F]Flortaucipir cutoffs for tau positivity and staging in Alzheimer’s disease
por: Quattrini, Giulia, et al.
Publicado: (2023) -
Molecular Image-Guided Theranostic and Personalized Medicine 2013
por: Zhang, Hong, et al.
Publicado: (2014) -
Molecular Image-Guided Theranostic and Personalized Medicine 2014
por: Zhang, Hong, et al.
Publicado: (2015) -
Parametric Estimation of Reference Signal Intensity for Semi-Quantification of Tau Deposition: A Flortaucipir and [(18)F]-APN-1607 Study
por: Zhang, Huiwei, et al.
Publicado: (2021)